Low-Dose PARP-1 Inhibitor Modulation of Tumor Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly those involving PARP inhibitors, face challenges in effectively targeting inflammation-driven cancers and maintaining therapeutic efficacy without inducing resistance or adverse effects, as high doses can lead to synthetic lethality issues and resistance in DNA repair-deficient cancers.
Innovation Solution
Administering a low-dose PARP inhibitor that partially inhibits PARP-1 activity, reducing its enzymatic activity by 10-50% to modulate the tumor microenvironment, specifically targeting myeloid-derived suppressor cells and immune cells without affecting cancer cells, and combining with anti-cancer immunotherapies for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose PARP inhibitors are administered to achieve complete PARP inhibition, then DNA repair-deficient cancer cells are effectively killed through synthetic lethality, but resistance develops and adverse effects increase
Solution Approach 1:
The patent applies partial inhibition of PARP-1 (reducing activity by 10-50% but not completely blocking it) to modulate the tumor microenvironment and enhance immunotherapy efficacy, rather than using complete inhibition which causes resistance and toxicity. This partial action approach allows sustained therapeutic effect without inducing resistance mechanisms in cancer cells.
Solution Approach 2:
The patent changes the dosage parameter from high-dose complete inhibition to low-dose partial inhibition (10-50% reduction in PARP-1 enzymatic activity). This parameter change transforms the therapeutic mechanism from direct cancer cell killing to immunomodulation, thereby reducing resistance development and adverse effects while maintaining efficacy.
2Productivity
If complete PARP-1 inhibition is used to treat cancer, then tumor cell death is maximized, but the tumor microenvironment and immune cell function are adversely affected
Solution Approach 1:
The patent creates different local effects of PARP-1 inhibition: partial inhibition in immune cells and stromal cells (preserving their function) versus complete inhibition in cancer cells (inducing death). This local quality differentiation allows selective action on different cell types within the tumor microenvironment, enhancing overall therapeutic efficacy while preserving immune function.
Solution Approach 2:
The patent uses partial PARP-1 inhibition (10-50% reduction) specifically in the tumor microenvironment to modulate immune cell function and reduce suppressor cell activity, while avoiding complete inhibition that would harm immune function. This partial action in specific compartments achieves therapeutic benefit without compromising microenvironment stability.
3Reliability
If PARP inhibitors are administered at standard doses, then DNA damage response is blocked, but inflammation-driven tumor progression is not effectively controlled
Solution Approach 1:
The patent changes the dosing parameter from standard high-dose regimens to low-dose regimens that achieve 10-50% PARP-1 inhibition. This parameter change shifts the primary mechanism from DNA damage response blockade to inflammation modulation, effectively controlling inflammation-driven tumor progression while maintaining DNA damage response inhibition.
Solution Approach 2:
The patent applies partial PARP-1 inhibition to achieve anti-inflammatory effects in the tumor microenvironment, which are insufficient at lower levels but excessive at standard doses. This partial action optimizes the balance between DNA damage response inhibition and inflammation control for inflammation-driven cancers.
Data Source
AI summary
The invention is directed to roles for low doses of PARP-1 inhibitors and synergistic combinations thereof to treat disease.